B. longum: safety and interactions

Tolerability of B. longum, antibiotics and situations requiring medical assessment.

Key points

  • In cases of severe illness or markedly weakened immunity, live probiotics may increase infection risk. Discuss product choice and monitoring with a doctor. [1] [2] [3] [4] [5] See the evidence 1
  • Antibiotics may reduce the effect of some live probiotics. Check the compatibility of the specific product and prescribed medicine with a doctor or pharmacist. [6] See the evidence 1
  • Live probiotics may cause gas and other intestinal complaints; reactions have also been described for inactivated HT-ES1. Also check the other ingredients in the chosen supplement. [1] [2] [3] [4] [5] See the evidence 1

Practical guide

Check the findings and their applicability to your situation.

Safety depends on the person’s condition and the product’s form and composition.

Key points

Why these conclusions

Tolerability and medicines

In healthy people, live probiotics can cause gas and other intestinal complaints. The trial of inactivated HT-ES1 described stomach pain, gas and a possible association with nausea, bloating and reflux. [1] [2] [3] [4] [5]

Antibiotics may reduce the effectiveness of some live probiotics; this depends on the medicine and bacteria. Check the instructions and compatibility of the chosen product with the prescribed antibiotic. [6]

The CLA8013 capsule shell in the trial described contained porcine gelatin and soy lecithin. Another product may have a different composition. [1] [2] [3] [4] [5]

Information from the source

In healthy people, live probiotics can cause gas and other intestinal complaints. Inactivated cells also do not rule out adverse reactions: the HT-ES1 trial described stomach pain, gas and a possible association with nausea, bloating and reflux. In severe illness or markedly weakened immunity, live probiotics may increase the risk of infection. In these situations, discuss product choice and monitoring with a doctor. The risk is particularly important for preterm infants: the FDA described a case of B. longum sepsis and the death of an infant after a hospital product containing live bacteria. This case does not establish the frequency of complications in healthy adults. Check not only the bacteria but also the other ingredients. For example, the CLA8013 capsule shell in the trial described contained porcine gelatin and soy lecithin; another product may have a different composition. [1] [2] [3] [4] [5]

Drug interactions

AgentInteractionWhat to considerSources
AntibioticsMay reduce the effectiveness of some live probiotics. This depends on the specific antibiotic and bacteria.Check the chosen product’s instructions and its compatibility with the prescribed antibiotic with a doctor or pharmacist.[6]

Information from the source

Live bacteria. BB536, NCC3001, 1714, 35624, ES1, BL21 and APC1472 are different strains. Look on the package for the full code, CFU count through the end of shelf life and storage conditions. More CFU alone does not mean more benefit. Inactivated cells. CLA8013 and HT-ES1 were heat-treated in these trials. Their doses are expressed as numbers of cells or cell equivalents, not numbers of live bacteria. Even for HT-ES1, doses differed: 2.5 billion cells in digestive studies and 2 billion for allergic rhinitis. Strain 35624. In an early publication it was called B. infantis 35624. In the trial of pain in IBS, capsules containing 100 million CFU daily showed an advantage; this is not a general result for all doses or all B. longum products. [5] [2] [1] [7]

More details

Particularly vulnerable groups

In severe illness or markedly weakened immunity, live probiotics require medical assessment. The FDA described a case of B. longum sepsis and the death of a preterm infant after a hospital product; this case does not establish the frequency of complications in healthy adults. [1] [2] [3] [4] [5]

Sources

  1. Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study. https://pubmed.ncbi.nlm.nih.gov/39599737/
  2. Effects of Bifidobacterium longum CLA8013 on bowel movement improvement: a placebo-controlled, randomized, double-blind study. https://pubmed.ncbi.nlm.nih.gov/37404567/
  3. Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA). https://www.fda.gov/safety/medical-product-safety-information/risk-invasive-disease-preterm-infants-given-probiotics-formulated-contain-live-bacteria-or-yeast
  4. Probiotics: Usefulness and Safety (NCCIH). https://www.nccih.nih.gov/health/probiotics-usefulness-and-safety
  5. Probiotics — Fact Sheet for Consumers (NIH ODS). https://ods.od.nih.gov/factsheets/Probiotics-Consumer/
  6. Dietary Supplements for Immune Function and Infectious Diseases — Health Professional Fact Sheet (NIH ODS). https://ods.od.nih.gov/factsheets/Immunefunction-HealthProfessional/
  7. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. https://pubmed.ncbi.nlm.nih.gov/16863564/

Methodology: Subpages evidence-led supplement pipeline v1

Ingredient overview: Bifidobacterium longum